China Pharma Holdings Gross Profit Growth & History (CPHI)
China Pharma Holdings's gross profit was −$131,950 for fiscal 2025.
View full China Pharma Holdings company overviewChina Pharma Holdings annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$131,950 | $1.9M | — |
| 2024 | 2024-12-31 | −$2.0M | −$1.7M | — |
| 2023 | 2023-12-31 | −$281,085 | $212,831 | — |
| 2022 | 2022-12-31 | −$493,916 | −$843,186 | — |
| 2021 | 2021-12-31 | $349,270 | −$1.6M | −82.12% |
| 2020 | 2020-12-31 | $2.0M | $470,722 | +31.76% |
| 2019 | 2019-12-31 | $1.5M | −$492,664 | −24.95% |
| 2018 | 2018-12-31 | $2.0M | −$493,702 | −20.00% |
| 2017 | 2017-12-31 | $2.5M | −$749,960 | −23.30% |
| 2016 | 2016-12-31 | $3.2M | $1.8M | +119.76% |
| 2015 | 2015-12-31 | $1.5M | −$1.2M | −45.11% |
| 2014 | 2014-12-31 | $2.7M | $3.1M | — |
| 2013 | 2013-12-31 | −$480,919 | −$14.6M | — |
| 2012 | 2012-12-31 | $14.1M | −$14.9M | −51.44% |
| 2011 | 2011-12-31 | $29.0M | −$1.3M | −4.28% |
| 2010 | 2010-12-31 | $30.3M | — | — |
China Pharma Holdings quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $83,566 | $170,576 | — |
| Q1 2026 | 2026-03-31 | $285,487 | $421,548 | — |
| Q4 2025 | 2025-12-31 | $150,775 | $311,364 | — |
| Q3 2025 | 2025-09-30 | −$59,654 | $459,995 | — |
| Q2 2025 | 2025-06-30 | −$87,010 | $928,376 | — |
| Q1 2025 | 2025-03-31 | −$136,061 | $153,963 | — |
| Q4 2024 | 2024-12-31 | −$160,589 | −$81,431 | — |
| Q3 2024 | 2024-09-30 | −$519,649 | −$286,459 | — |
| Q2 2024 | 2024-06-30 | −$1.0M | −$868,725 | — |
| Q1 2024 | 2024-03-31 | −$290,024 | −$467,948 | — |
| Q4 2023 | 2023-12-31 | −$79,158 | −$121,840 | — |
| Q3 2023 | 2023-09-30 | −$233,190 | −$95,434 | — |
| Q2 2023 | 2023-06-30 | −$146,661 | $82,720 | — |
| Q1 2023 | 2023-03-31 | $177,924 | $347,385 | — |
| Q4 2022 | 2022-12-31 | $42,682 | −$259,254 | −85.86% |
| Q3 2022 | 2022-09-30 | −$137,756 | $158,640 | — |
| Q2 2022 | 2022-06-30 | −$229,381 | −$300,381 | — |
| Q1 2022 | 2022-03-31 | −$169,461 | −$442,191 | — |
| Q4 2021 | 2021-12-31 | $301,936 | −$259,537 | −46.22% |
| Q3 2021 | 2021-09-30 | −$296,396 | −$343,592 | — |
| Q2 2021 | 2021-06-30 | $71,000 | −$1.1M | −93.83% |
| Q1 2021 | 2021-03-31 | $272,730 | $78,291 | +40.27% |
| Q4 2020 | 2020-12-31 | $561,473 | $272,126 | +94.05% |
| Q3 2020 | 2020-09-30 | $47,196 | −$325,563 | −87.34% |
| Q2 2020 | 2020-06-30 | $1.1M | $986,250 | +603.03% |
| Q1 2020 | 2020-03-31 | $194,439 | −$462,091 | −70.38% |
| Q4 2019 | 2019-12-31 | $289,347 | $460,225 | — |
| Q3 2019 | 2019-09-30 | $372,759 | −$139,786 | −27.27% |
| Q2 2019 | 2019-06-30 | $163,548 | −$415,933 | −71.78% |
| Q1 2019 | 2019-03-31 | $656,530 | −$397,170 | −37.69% |
| Q4 2018 | 2018-12-31 | −$170,878 | −$851,679 | — |
| Q3 2018 | 2018-09-30 | $512,545 | $91,006 | +21.59% |
| Q2 2018 | 2018-06-30 | $579,481 | −$68,876 | −10.62% |
| Q1 2018 | 2018-03-31 | $1.1M | $335,847 | +46.78% |
| Q4 2017 | 2017-12-31 | $680,801 | −$1.1M | −61.00% |
| Q3 2017 | 2017-09-30 | $421,539 | $71,571 | +20.45% |
| Q2 2017 | 2017-06-30 | $648,357 | $166,260 | +34.49% |
| Q1 2017 | 2017-03-31 | $717,853 | $77,034 | +12.02% |
| Q4 2016 | 2016-12-31 | $1.7M | $1.6M | +1153.49% |
| Q3 2016 | 2016-09-30 | $349,968 | $27,968 | +8.69% |
| Q2 2016 | 2016-06-30 | $482,097 | $537,924 | — |
| Q1 2016 | 2016-03-31 | $640,819 | −$418,308 | −39.50% |
| Q4 2015 | 2015-12-31 | $139,261 | $4.1M | — |
| Q3 2015 | 2015-09-30 | $322,000 | −$1.2M | −78.66% |
| Q2 2015 | 2015-06-30 | −$55,827 | −$2.5M | — |
| Q1 2015 | 2015-03-31 | $1.1M | −$1.6M | −60.19% |
| Q4 2014 | 2014-12-31 | −$3.9M | −$619,265 | — |
| Q3 2014 | 2014-09-30 | $1.5M | −$728,202 | −32.55% |
| Q2 2014 | 2014-06-30 | $2.4M | $267,252 | +12.43% |
| Q1 2014 | 2014-03-31 | $2.7M | $4.2M | — |
| Q4 2013 | 2013-12-31 | −$3.3M | −$4.7M | — |
| Q3 2013 | 2013-09-30 | $2.2M | −$1.0M | −31.03% |
| Q2 2013 | 2013-06-30 | $2.2M | −$2.0M | −48.04% |
| Q1 2013 | 2013-03-31 | −$1.6M | −$6.9M | — |
| Q4 2012 | 2012-12-31 | $1.4M | −$5.9M | −81.02% |
| Q3 2012 | 2012-09-30 | $3.2M | −$4.3M | −56.84% |
| Q2 2012 | 2012-06-30 | $4.1M | −$3.1M | −43.17% |
| Q1 2012 | 2012-03-31 | $5.3M | −$1.6M | −22.79% |
| Q4 2011 | 2011-12-31 | $7.3M | — | — |
| Q3 2011 | 2011-09-30 | $7.5M | −$110,215 | −1.45% |
| Q2 2011 | 2011-06-30 | $7.3M | $238,047 | +3.38% |
| Q1 2011 | 2011-03-31 | $6.9M | — | — |
| Q3 2010 | 2010-09-30 | $7.6M | — | — |
| Q2 2010 | 2010-06-30 | $7.0M | — | — |
China Pharma Holdings gross profit trends
Over the last five fiscal years, China Pharma Holdings's gross profit decreased from $2.0M to −$131,950, a change of −$2.1M. The latest reported quarter, Q2 2026, shows $83,566.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China Pharma Holdings source filings ↗